Literature DB >> 8167348

Photochemical inactivation of pathogenic bacteria in human platelet concentrates.

L Lin1, H Londe, J M Janda, C V Hanson, L Corash.   

Abstract

Platelet concentrates (PC) may be infrequently contaminated with low levels of bacteria that can cause septicemia and death in patients receiving transfusion therapy. We evaluated the efficacy of a photochemical decontamination (PCD) technique using 8-methoxypsoralen (8-MOP) and long wavelength UV light (UVA) to inactivate bacteria in standard therapeutic PC. Twelve phylogenetically distinct pathogenic bacteria, 5 gram-positive and 7 gram-negative organisms, were seeded into PC to a final challenge dose ranging from 10(5) to 10(7) colony-forming units (CFU)/mL. Contaminated PC were treated with 8-MOP (5 micrograms/mL) and 5 J/cm2 of UVA, a PCD treatment regimen found to adequately preserve in vitro platelet function. Greater than 10(5) CFU/mL of all 5 gram-positive (Staphylococcus aureus, Streptococcus epidermidis, Streptococcus pyogenes, Listeria monocytogenes, and Corynebacterium minutissimum) and 2 of the gram-negative (Escherichia coli and Yersinia enterocolitica) organisms were inactivated. The remaining 5 gram-negative organisms were more resistant, with less than 10(1) to 10(3.7) CFU/mL inactivated under these conditions. The inactivation efficiency for this resistant group of gram-negative organisms was improved when PC were resuspended in a synthetic storage medium with reduced plasma protein concentration (15%) and an increased 8-MOP concentration (23.4 micrograms/mL). Illumination with 3 J/cm2 of UVA in this system inactivated greater than 10(5) CFU/mL of 4 resistant gram-negative organisms (Salmonella choleraesuis, Enterobacter cloacae, Serratia marcescens, and Klebsiella pneumoniae) and 10(4.1) CFU/mL of the most resistant gram-negative organism (Pseudomonas aeruginosa). This level of PCD treatment did not adversely affect in vitro platelet function. These results demonstrate that PCD using 8-MOP (5 to 23.4 micrograms/mL) effectively inactivated high levels of pathogenic bacteria in PC with adequate preservation of in vitro platelet properties.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8167348

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  6 in total

1.  Laboratory Evaluation of the Effectiveness of Pathogen Reduction Procedures for Bacteria.

Authors:  Thomas H Müller; Thomas Montag; Axel W Seltsam
Journal:  Transfus Med Hemother       Date:  2011-07-08       Impact factor: 3.747

2.  Transfusion-related Listeria monocytogenes infection in a patient with acute myeloid leukaemia.

Authors:  Giulia Tolomelli; Pier Luigi Tazzari; Michela Paolucci; Mario Arpinati; Maria P Landini; Pasqualepaolo Pagliaro
Journal:  Blood Transfus       Date:  2014-06-05       Impact factor: 3.443

3.  Rapid screening method for detection of bacteria in platelet concentrates.

Authors:  S Ribault; K Harper; L Grave; C Lafontaine; P Nannini; A Raimondo; I Besson Faure
Journal:  J Clin Microbiol       Date:  2004-05       Impact factor: 5.948

4.  The pharmacokinetics of 8-methoxypsoralen following i.v. administration in humans.

Authors:  V Billard; P L Gambus; J Barr; C F Minto; L Corash; J W Tessman; J L Stickney; S L Shafer
Journal:  Br J Clin Pharmacol       Date:  1995-10       Impact factor: 4.335

5.  Growth inhibition of mammalian cells by synthetic and natural photosensitising agents.

Authors:  A M Christodoulopoulos; J J Osman; H C Lynch
Journal:  Cytotechnology       Date:  2002-05       Impact factor: 2.058

6.  Evaluation of amotosalen and UVA pathogen-reduced apheresis platelets after 7-day storage.

Authors:  Jose A Cancelas; Jamie R Genthe; Moritz Stolla; Neeta Rugg; S Lawrence Bailey; Shawnagay Nestheide; Beth Shaz; Samantha Mack; Kadi Schroeder; Waseem Anani; Zbigniew M Szczepiorkowski; Larry J Dumont; Subramanian Yegneswaran; Laurence Corash; Nina Mufti; Richard J Benjamin; Anna C Erickson
Journal:  Transfusion       Date:  2022-07-09       Impact factor: 3.337

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.